Related Experiment Video

Updated: Apr 8, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives

Yajing Liu1,2, Yuwei Liu1,2, Tingting Wu1,2

  • 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Cancer Biology & Medicine
|April 7, 2026
PubMed

Insights

Antibody-drug conjugates (ADCs) offer targeted cancer therapy by linking antibodies to chemotherapy. Overcoming drug resistance is key to maximizing their therapeutic potential.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, merging antibody specificity with cytotoxic payloads.
  • This approach aims to improve therapeutic efficacy and reduce systemic toxicity in oncology.
  • ADCs leverage targeted delivery to enhance cancer cell killing.

Purpose of the Study:

  • To provide a comprehensive review of antibody-drug conjugate (ADC) development and clinical success.
  • To analyze mechanisms of drug resistance encountered with ADCs.
  • To propose strategies for overcoming resistance and advancing ADC therapeutics.

Main Methods:

  • Literature review of ADC structural and mechanistic foundations.
  • Analysis of clinically successful ADCs.
  • Discussion of resistance mechanisms and potential therapeutic strategies.

Main Results:

  • ADCs have demonstrated remarkable progress in cancer treatment.
  • Drug resistance, including target antigen alterations and intracellular trafficking defects, poses a significant challenge.
  • Next-generation ADCs, combination therapies, and multi-pathway targeting are promising strategies.

Conclusions:

  • Innovative approaches are crucial for overcoming ADC resistance.
  • Further development is needed to fully realize the therapeutic promise of ADCs in cancer.
  • Addressing resistance mechanisms will expand the clinical application of ADCs.
Keywords:
Antibody-drug conjugatescancer therapycombination strategiesdrug resistance

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
115
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.1K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.9K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.2K